Lower all-cause mortality rates in patients harboring pituitary carcinoma following the introduction of temozolomide

ConclusionsIn this large cancer-database-based analysis we observed improved overall survival in patients harboring PC in the years following the introduction of TMZ.

http://link.springer.com/10.1007/s12020-019-01996-9

Source: Endocrine - July 1, 2019 Category: Endocrinology Source Type: research